Lowden

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lowden

Quick Facts

Property Description
Active ingredient Atorvastatin
Form Film-coated tablet
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Managing high blood cholesterol and lipids
Origin Synthetic

Identity and Classification

Lowden is a prescription-only synthetic medicine containing the active component Atorvastatin. The drug is formally identified as belonging to the HMG-CoA reductase inhibitors class, which are widely recognized as statins. Lowden is supplied as a single-ingredient medicine in a film-coated tablet form, designed for oral administration and systemic absorption, distinguishing it from combination therapies or topical agents.

Atorvastatin is a clinically recognized compound, supported by pharmacological studies demonstrating its established efficacy in systemic lipid management. Atorvastatin is approved for the treatment of dyslipidemia. This medicine is recognized as an effective tool for people looking to lower their cholesterol and manage related health risks.

General Purpose and Mechanism of Action

The overarching purpose of Lowden is to act as an antilipemic agent, used as an adjunct to diet and lifestyle changes to manage and control elevated blood lipid levels, such as hypercholesterolemia (high cholesterol). Its action is achieved by selectively inhibiting the key liver enzyme HMG-CoA reductase.

By competitively blocking this enzyme, the Atorvastatin effectively reduces the liver's ability to initiate cholesterol biosynthesis. Statins work by slowing the body's cholesterol production to decrease the amount of low-density lipoprotein (LDL) cholesterol—the “bad” cholesterol—that can accumulate in the arteries. This mechanism works internally to keep your blood lipid levels balanced. A typical scenario for its use involves patients requiring long-term intervention to reduce cardiovascular risk factors associated with persistently high cholesterol levels.

Regulatory References

  1. MedlinePlus Statins Overview

What side effects are possible with Lowden?

Adverse Reaction Scope

The possible side effects of Lowden (Atorvastatin) are formally classified by frequency and system-organ class in regulatory documents, such as those from the FDA and EMA. The most commonly reported adverse reactions (incidence ge 5%) include nasopharyngitis, arthralgia (joint pain), diarrhea, pain in extremity, and urinary tract infection. These reactions involve the Infections and Infestations, Musculoskeletal, Gastrointestinal, and Renal system-organ classes.


Serious Adverse Reactions and Safety Limitations

Official labels document rare but clinically significant adverse reactions. The major serious safety concern is Myopathy (muscle pain, tenderness, or weakness) which can, in rare cases, progress to Rhabdomyolysis, a severe condition that may lead to acute kidney injury. Rare reports of fatal and non-fatal hepatic failure are also documented, and a risk of Hemorrhagic Stroke was observed in a specific trial using the highest dose (80 mg) in certain patients with a recent stroke or TIA.


Regulatory Safety Structure

Classification Tier Primary Safety Concerns
Common Nasopharyngitis, Arthralgia, Diarrhea, Pain in extremity
Rare Rhabdomyolysis, Hepatic Failure, Immune-Mediated Necrotizing Myopathy (IMNM)
Population-Specific Risk Age (ge 65 years), Renal impairment, Uncontrolled hypothyroidism

Safety-Related Restrictions: The medication is formally contraindicated in individuals with active liver disease (including unexplained persistent elevations in liver enzymes) and during pregnancy and lactation. Risk factors for myopathy, such as advanced age and impaired kidney function, are explicitly highlighted in the official prescribing information. Liver enzyme monitoring is advised prior to and during therapy as clinically indicated.

The official safety information structures the understanding of risk by clearly delineating common, generally manageable effects from the rare, serious events concerning muscle and liver function, which necessitate specific safety constraints.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation for Lowden (Atorvastatin) establishes the management protocol required during an overdose, rather than detailing a unique profile of specific symptoms. Specific clinical manifestations or laboratory abnormalities that are exclusive to an acute overdosage scenario are not formally detailed in the official Overdosage sections of government labels.

Required Emergency Actions

In the event of a suspected Lowden overdose, official regulatory guidance mandates immediate contact with your regional poison control centre for specialized management. The requirement to seek medical attention is necessary because the official labeling unequivocally states that no specific treatment or antidote is known for Atorvastatin overdosage.

Regulatory Management Protocol

Regulatory authorities stipulate that if an overdose occurs, the patient must be treated symptomatically, and comprehensive supportive measures instituted as required based on the patient’s clinical status. The prescribing information further guides procedural actions by noting that hemodialysis is not expected to significantly enhance drug clearance in an overdose situation. This limitation is officially documented because of the active component’s extensive binding to plasma proteins, which constrains the available options for intoxication management.

Therapeutic Uses of Lowden

What Lowden Treats: Main Uses and Benefits

Lowden is commonly used across domains where additional symptomatic support is needed to address symptoms related to systemic imbalance, specifically those linked to elevated lipid levels. This use includes managing high levels of cholesterol and triglycerides. It contributes to easing the overall symptom load by targeting these underlying clusters, which is relevant in contexts involving heightened systemic burden and assists with maintaining functional stability over time.


Lowden is relevant in conditions involving episodic or fluctuating manifestations where long-term intervention supports the patient’s health goals. It is applied in addressing the heightened risk factors, such as those in Type 2 Diabetes patients, which may influence functional stability. By assisting with maintaining functional stability, Lowden is relevant for easing the potential for future acute events, including serious cardiovascular events.

Quick Fact: Therapeutic Use Focus
Primary Therapeutic Goal Reduction of long-term cardiovascular event risk
Symptom Cluster Addressed Elevated lipids (LDL-C, Total Cholesterol, Triglycerides)
Patient Benefit Supports maintenance of functional stability over time

Regulatory References

  1. NIH MedlinePlus overview on Atorvastatin

Eligibility and Restrictions for Use

Lowden is a medication primarily prescribed to lower cholesterol and triglyceride levels in the blood, often in combination with diet and exercise. This treatment is aimed at reducing the risk of cardiovascular events like heart attack and stroke.

Who Can Use Lowden?

Lowden is generally suitable for adults with elevated total cholesterol or triglyceride levels that haven't responded adequately to non-pharmacological interventions. It is also sometimes prescribed for patients who have already experienced a heart attack or stroke to prevent recurrence.

Patient Group Indication
Adults with hypercholesterolemia To lower LDL-C and total cholesterol
Adults with hypertriglyceridemia To lower elevated triglyceride levels
Patients at high cardiovascular risk For primary and secondary prevention

Who Cannot Use Lowden?

Certain conditions and life stages represent contraindications for using Lowden, as the risks outweigh the potential benefits. This includes individuals with known active liver disease or persistent, unexplained elevations in liver function tests. Furthermore, Lowden is unsafe for use during pregnancy or in women who are breastfeeding, due to the potential for harm to the developing baby or infant.

Individuals with a history of allergic reactions to any component of the medication should not use it. Caution and potential dose adjustments are necessary for patients with severe kidney impairment or a history of muscle disorders.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Lowden

Interaction scope

Medicinal product categories with documented interactions: Strong and Moderate CYP3A4 Inhibitors, OATP1B1/BCRP Transporter Inhibitors, Fibrates, and specific Antiviral Agents.

Specific interacting medicines (if explicitly listed): Glecaprevir/Pibrentasvir, Cyclosporine, Tipranavir plus Ritonavir, Clarithromycin, Itraconazole, Rifampin, and Colchicine.

Mechanistic basis of interactions (only if stated in label): The majority of clinically significant interactions are due to Inhibition/Induction of the CYP3A4 enzyme or Inhibition of the OATP1B1 and BCRP uptake/efflux transporters. These processes officially alter the plasma concentration (AUC/Cmax) of Atorvastatin.

Timing-based interaction rules (if applicable): Co-administration with Rifampin must occur simultaneously to prevent a significant regulatory-documented decrease in Atorvastatin concentrations.

Population-specific interaction notes (if applicable): In patients with Hepatic Impairment, systemic Atorvastatin plasma concentrations are markedly increased, which influences the potential severity of concurrent interaction risks.

Interaction-related restrictions: Consumption of Grapefruit Juice in large quantities is documented to increase Atorvastatin plasma levels. Certain strong CYP3A4 inhibitors require an official maximum daily dose limitation of Atorvastatin.


Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Combinations with Glecaprevir/Pibrentasvir are strictly Contraindicated. Combinations with Fibrates and Colchicine are classified under Pharmacodynamic Additive Risk, increasing the likelihood of skeletal muscle adverse effects.

Regulatory basis (EMA / FDA / etc.): Information is derived from the official prescribing information documents published by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) equivalent.

Interaction-context constraints (as defined in official documents): The documented effects are primarily pharmacokinetic, resulting in an officially stated increase or decrease in the plasma AUC and Cmax of Atorvastatin or co-administered drugs.

Resulting interaction structure

Official interaction statements:

  • The combination with Glecaprevir/Pibrentasvir is classified as a strictly prohibited co-administration.
  • Strong inhibitors of the CYP3A4 metabolic pathway, such as Itraconazole, increase Atorvastatin systemic exposure, necessitating maximum dose limitations.
  • Inhibition of the OATP1B1 uptake transporter, such as by Cyclosporine, leads to a documented increase in Atorvastatin plasma concentrations.
  • Co-administration with Fibrates or Colchicine carries a regulatory warning for an additive pharmacodynamic risk of myopathy/rhabdomyolysis.

Connection to the overall interaction profile: The regulatory interaction structure for Lowden is defined by strict exposure constraints imposed by potent inhibitors of metabolic enzymes and transport proteins. These constraints lead to formal prohibitions, mandated dose restrictions, and specific administration timing rules to manage documented concentration changes.

Mechanism of Action

How Lowden Works

The action of Lowden (Atorvastatin) is determined by two highly coordinated mechanistic domains that govern the body's cholesterol management, leading to changes in systemic lipid clearance.


⏹️ Molecular Inhibition of Cholesterol Synthesis

This domain involves the active ingredient acting as a competitive inhibitor of HMG-CoA reductase, the enzyme responsible for the rate-limiting step in the liver's Mevalonate pathway. By halting this primary step, the drug reduces the body's internal, or endogenous, production of cholesterol, causing a shift in hepatic cholesterol balance.


⬆️ Upregulation of LDL Receptors and Clearance

The resulting drop in the liver's internal cholesterol pool triggers a physiological feedback mechanism, causing the upregulation of Hepatic LDL Receptors on the surface of liver cells. This increase in receptor density enhances the liver's capacity to actively capture and remove circulating Low-Density Lipoprotein Cholesterol (LDL-C) from the bloodstream, thereby modulating systemic lipid concentrations.


Pleiotropic Modulation of Vascular Pathways

Beyond its primary lipid-lowering cascade, the mechanism of Atorvastatin also includes molecular actions, known as pleiotropic effects, that modulate the function of the blood vessel lining (the endothelium). This influences activity within local vascular pathways and affects the physiological environment of the blood vessels.

Dosage and Administration Information

How to Use Lowden: Official Administration Guidelines

Lowden, which contains the active ingredient Atorvastatin, is administered exclusively via the oral route as a film-coated tablet. The medicine is prescribed to be taken as a single dose once daily and can be consumed at any time of the day, either with or without food, providing flexibility for the daily routine. Its use is consistently defined as an **adjunct to a standard cholesterol-lowering diet.

Dosing and Titration Schedule

The official adult dosing regimen typically begins with 10 mg or 20 mg once daily. However, a higher initial dose of 40 mg may be used when a greater reduction in cholesterol is required. The approved maintenance range is 10 mg to 80 mg daily. Any adjustment to the dosage, known as titration, must be conducted at intervals of four weeks or more to allow for the assessment of the lipid response before progressing toward the maximum approved dose of 80 mg.

Specific Use Instructions

Missed Dose Handling: If a dose is missed, the standard procedure is to skip the missed dose entirely and simply resume with the next scheduled dose. This reinforces the importance of maintaining the ongoing daily schedule and avoiding double dosing. Dose Adjustments: No dose adjustment is required for patients with impaired kidney function. However, specific dose limitations must be observed when Lowden is co-administered with certain strong CYP3A4 inhibitors (e.g., clarithromycin); the daily dose must not exceed 20 mg in these situations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lowden (Atorvastatin)


Evidence for Preventing Major Cardiovascular Events

For the indications Lowden is studied for, large-scale, long-term Randomized Controlled Trials (RCTs) were conducted. These studies explored outcomes related to systemic or functional imbalance, specifically serious clinical events such as non-fatal heart attacks, fatal coronary heart disease, and strokes. The primary study populations involved adults with established coronary conditions (secondary prevention) and those with multiple cardiovascular risk factors, such as high blood pressure and Type 2 Diabetes (primary prevention).

Findings describe patterns observed in these studies, where cohorts receiving the medicine were monitored for the time it took for a major cardiovascular event to occur, compared to groups receiving a placebo or an active comparator. These studies contribute to the broader evidence landscape by describing how event rates evolved in these high-risk group patterns.

Evidence for Managing Cholesterol and Lipids

Research examining blood lipid outcomes in trials using Lowden as an intervention involved short-term and intermediate-term Randomized Controlled Trials. Researchers monitored physiological markers, specifically concentrations of cholesterol in the blood, including Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, and triglycerides in adults with elevated baseline lipid levels.

Research highlights changes measured during the study period, with data showing patterns related to shifts in LDL-C concentrations. Studies reported that the magnitude of these measured changes was also evaluated based on the administered dose. This provides insight into short-term changes in lipid levels, with the maximum observed change often occurring early in the study period.

What Scientific Consensus Identifies as Uncertain or Limited

Scientific reviews and meta-analyses consistently highlight areas where data remain limited. Long-term effects are not fully established for treatment spanning entire decades, as the longest controlled trials lasted less than a decade. There is limited information for long-term outcomes in very specific, uncommon patient groups.

Furthermore, sample sizes were modest or small in specific subgroup studies, such as those involving patients with certain rare genetic lipid disorders or younger children. Consequently, certainty remains low for these specific populations.

Research does not determine whether an individual will respond similarly to the group patterns described in the studies. Study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study: Efficacy and Safety of High-Dose Atorvastatin vs Simvastatin
  2. National Institute for Health and Care Excellence (NICE) Clinical Guideline: Lipid modification

Frequently Asked Questions (FAQ)

Common questions about Lowden (FAQ)


Q: How long does it usually take to notice Lowden working?

According to official product information, the maximum cholesterol-lowering effect is generally observed after two to four weeks of starting therapy. Changes in your lipid levels are monitored by a healthcare professional during this time. The medicine is typically taken as prescribed to support the intended therapeutic goal.


Q: Is it normal to feel a little dizzy after starting Lowden?

Dizziness has been reported as an adverse reaction in the post-marketing setting after the medicine became available to the public. However, official sources note that the exact frequency of this effect is not known. Such experiences are generally brought to the attention of a healthcare professional.


Q: Do food or drinks affect how Lowden works?

Regulatory information states that the tablets can be taken with or without food. However, consuming large quantities of grapefruit juice is documented to increase the amount of Lowden in the body. Any dietary concerns, such as the consumption of grapefruit juice, are generally reviewed with a healthcare provider.


Q: Why do people sometimes say Lowden makes them tired?

Unusual tiredness or weakness is listed as a possible side effect in official documents. It is important to know that extreme tiredness can also be an early sign associated with rare but serious muscle problems. Significant changes in energy levels or weakness are typically reported to a healthcare provider.


Q: Is Lowden addictive?

No, Lowden belongs to the statin class of medications, which are HMG-CoA reductase inhibitors. The drug is not classified as a controlled substance and is not associated with addictive properties.


Q: Does Lowden interact with common pain relievers like ibuprofen?

The official interaction map for Lowden does not explicitly list common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen as a critical pharmacokinetic interaction. Official guidance recommends that all over-the-counter medicines, including pain relievers, be reviewed with a healthcare provider.


Q: Can Lowden be used by older adults?

Lowden is generally considered appropriate for use in older adults, as studies have not shown unique, limiting problems in this group. However, official information highlights that patients 65 years or older may have an increased risk of developing certain muscle problems, and monitoring by a healthcare professional is generally recommended.


Q: Are there any long-term effects of taking Lowden?

The medicine is intended for long-term use, and the effectiveness of taking the drug over many years for reducing cardiovascular risk is supported by clinical trials. However, studies specifically tracking effects for multiple decades remain limited in official research documents.


Q: Is Lowden a brand name or is it available as a generic version?

The active ingredient in Lowden is Atorvastatin Calcium, which is the official generic name for the drug substance. Atorvastatin is widely available as a generic medicine, alongside various brand names.


Q: Are there any specific lifestyle changes recommended while taking Lowden?

Regulatory documents describe treatment with Lowden as an adjunct to a cholesterol-lowering diet. Furthermore, official information advises patients to implement and maintain general healthy lifestyle practices, such as regular exercise and avoiding smoking or excessive alcohol consumption.


Q: What are the most common reasons someone would stop taking Lowden?

Official documents advise temporary or permanent discontinuation if a patient develops severe muscle pain or weakness, experiences signs of liver damage, or has an acute serious illness or major surgery. Decisions regarding stopping or interrupting treatment are determined through consultation with a healthcare professional.


Q: Do I need to get blood tests while taking Lowden?

Yes, official guidance states that laboratory tests, specifically to check liver enzyme levels, are advised as a safety precaution. These tests are performed before starting treatment and then periodically during therapy as clinically indicated by your doctor.


Q: Are there different strengths or forms of Lowden?

The drug is officially available as film-coated tablets in multiple strengths, typically ranging from 10 mg up to 80 mg. Depending on the specific market, it may also be available as an oral suspension or a chewable tablet.


Q: Does Lowden have a black box warning?

Yes, the regulatory label for Atorvastatin includes a Boxed Warning regarding the rare but serious risk of cognitive impairment. This is a severe caution required by the FDA to draw attention to potential side effects in certain patient groups.


Q: Can children or teenagers use Lowden?

According to official regulatory approval, the drug is safe and effective for use in pediatric patients 10 years of age and older for specific types of high cholesterol. Safety and efficacy have not been established in children younger than 10 years old.


Q: Is it common to have skin rashes from Lowden?

Skin rash is listed as an uncommon side effect, meaning it affects less than 1 in 100 people who take the medicine. It is also important to note that a rash can, in rare cases, be a symptom of a severe allergic reaction.


Q: Can Lowden affect sleep patterns?

Official documents list insomnia, or trouble sleeping, as a common side effect of the medicine. If you notice persistent changes in your sleep patterns, these concerns are typically reported to a healthcare provider.


Q: Does Lowden interact with alcohol?

Regulatory information advises that a patient's alcohol use is generally a topic for discussion with their healthcare provider. This is because excessive or heavy consumption of alcohol may increase the risk of liver problems associated with the medicine.


Q: What if Lowden doesn't seem to be helping my condition?

Stopping Lowden is not recommended without consulting a healthcare professional. Your doctor monitors your condition by checking lipid levels and may adjust the dosage at intervals of four weeks or more to help achieve the intended therapeutic goal.


Q: Is Lowden safe for people with kidney disease?

Official administration guidelines state that no dose adjustment is typically required for patients with impaired kidney function. However, impaired kidney function is explicitly highlighted as a risk factor for developing muscle problems.


Q: Does Lowden interact with herbal products like St. John's Wort?

Official guidance recommends that all herbal products, supplements, and vitamins be discussed with a healthcare provider. This is because there may be insufficient data regarding the safety and potential drug-drug interactions of all herbal remedies.


Q: What are the main things I need to tell my doctor before starting Lowden?

Official guidance suggests that the medical history shared with the prescribing doctor typically includes any known allergies, a history of liver disease, and a history of muscle pain or weakness. This also includes all current prescription, over-the-counter, and herbal products being taken.


Q: Does Lowden affect birth control pills?

Studies indicate that the drug may slightly increase the levels of hormones in some oral contraceptives. It is also important to note that severe diarrhea, a possible side effect, may affect the efficacy of the birth control pill.


Q: Can Lowden cause changes in mood?

Mood-related effects, such as depression and nightmares, have been reported in the post-marketing safety setting. Any persistent mood changes or mental health concerns are generally reported to a healthcare professional.


Q: When was Lowden approved by the regulatory bodies?

The active ingredient in Lowden, Atorvastatin, received its initial approval from the U.S. Food and Drug Administration (FDA) in 1996 for the treatment of elevated cholesterol levels.


Q: Does Lowden require a special prescription or monitoring program?

Official regulatory documents indicate that while liver enzyme monitoring is advised as a safety precaution, the drug is not generally subject to a special prescription or formalized monitoring program like REMS (Risk Evaluation and Mitigation Strategy).


Q: Can Lowden be crushed or split?

The film-coated tablets are typically swallowed whole. Altering the tablet by crushing, splitting, or chewing is generally not recommended, unless the patient is specifically prescribed an alternative form, such as an oral suspension.

How should Lowden be stored and disposed of?

Lowden (Atorvastatin) must be stored under specific regulatory conditions to maintain its stability and effectiveness. The tablets are required to be kept at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The product must be protected from excessive heat, moisture, and direct light, and must not be frozen. The container should remain tightly closed.

All medicine must be stored out of the sight and reach of children.

For disposal, the FDA recommends using a drug take-back program as the preferred method for unused or expired tablets. If this is unavailable, the medicine should be removed from its original container, mixed with an undesirable substance (e.g., coffee grounds), and placed in a sealed bag before disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lowden found in:

A-Z Index: